@article{b0137717f11b4db2ae259ec8830092a1,
title = "Sleep loss in male rats contributes more to weight gain during sleep disruption than stress assessed by corticosterone",
abstract = "Sleep disruption (SD) promotes stress which may mediate the effect of SD induced by noise on bodyweight gain and food intake. We determined if the change in bodyweight during SD caused by noise was driven by stress (assessed by corticosterone) and whether the effects of noise on SD, stress and bodyweight were specific to the method of SD or a consequence of SD per se. We isolated stress from SD due to noise by exposing rats to noise during the darkphase to test whether darkphase noise stimulated weight gain, stress and food intake. Male Sprague-Dawley rats slept undisturbed, were exposed to noise during both circadian phases (lightphase vs darkphase) and lightphase gentle handling. Bodyweight, food intake, physical activity, vigilance states, and plasma corticosterone were determined. Darkphase noise did not affect vigilance states. Unlike lightphase noise, darkphase noise and lightphase gentle handling did not stimulate weight gain or food intake. Only gentle handling significantly increased corticosterone levels. Noise during the lightphase increasesed weight gain and food intake by causing SD and these effects were not driven by stress as assessed by corticosterone. These results may have significant implications for developing translational models of insomnia-induced obesity in humans.",
keywords = "Arousal, Brain, Insomnia, Obesity, Sleep disruption",
author = "Houser, {Monica M.} and Coborn, {Jamie E.} and Sinton, {Christopher M.} and Perez-Leighton, {Claudio E.} and Teske, {Jennifer A.}",
note = "Funding Information: Declarations of interest: none. The authors declare no conflicts of interest. The authors thank D.Dominguez, L.Troeger, D.Scali, K.Savage, and S.Wren for technical assistance. Dr. Coborn is now employed by Novo Nordisk Inc. and participated in the studies while at the University of Arizona. Funding for this research was supported by the National Institutes of Health [NS099468-01A1], a grant Fondecyt Regular [1200578], and the U.S. Department of Agriculture [ARZT-1372540-R23-131]. Funding sources had no involvement in the study design or in the decision to submit the article for publication. Funding Information: Declarations of interest: none. The authors declare no conflicts of interest. The authors thank D.Dominguez, L.Troeger, D.Scali, K.Savage, and S.Wren for technical assistance. Dr. Coborn is now employed by Novo Nordisk Inc. and participated in the studies while at the University of Arizona. Funding for this research was supported by the National Institutes of Health [ NS099468-01A1 ], a grant Fondecyt Regular [1200578], and the U.S. Department of Agriculture [ARZT-1372540-R23-131]. Funding sources had no involvement in the study design or in the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2023",
month = jan,
day = "1",
doi = "10.1016/j.neulet.2022.136959",
language = "English (US)",
volume = "792",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
}